Aldeyra Therapeutics, Inc. (ALDX) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-03-31

Key Insights

The reporting person, Todd C. Brady, the President and CEO of Aldeyra Therapeutics, Inc., acquired a significant number of stock options (1,880,510) and bonus units (632,318) on March 27, 2026, suggesting strong confidence in the company's future.
The stock options and bonus units granted to the reporting person have a four-year vesting schedule, aligning his incentives with long-term shareholder value creation.
The reporting person's substantial equity grants indicate the company's commitment to retaining and incentivizing its key executive, which could be viewed positively by investors.

Want the newest filings?

This analysis covers the filing from 2026-03-31. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-03-20

Richard Douglas, a director of Aldeyra Therapeutics, Inc., has purchased 70,000 shares of the company's common stock at $1.40 per share, increasing his direct ownership to 195,000 shares.
This insider buying activity suggests that Douglas has a positive outlook on the company's prospects and believes the stock is undervalued at the current trading price.
Investors should monitor any further insider trading activities as they can provide insights into management's confidence in the company's future performance.

Filed: 2026-03-19

Michael Alfieri, the Principal Financial Officer of Aldeyra Therapeutics, Inc. (ALDX), has purchased 5,000 shares of the company's common stock at a price of $1.42 per share.
This insider buying activity suggests that Alfieri is bullish on the company's prospects and believes the stock is undervalued at the current market price.
Insider buying can be a positive signal for investors, as it indicates that a company's management has confidence in the business and its future performance.

Other reports for Aldeyra Therapeutics, Inc.

Current Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.